By Michael Quiel
Investigative Reporter, US~Observer
Quantum BioPharma Ltd. (QNTM), previously known as FSD Pharma Inc., is a biotech company working on new treatments for serious brain and nervous system diseases, including multiple sclerosis (MS). Their most promising drug, Lucid-MS, is designed to stop and even repair the damage MS causes to the protective coating around nerves (called myelin). In early lab tests using mice with an MS-like condition, the drug helped the animals recover faster, kept more myelin intact, and restored their ability to move normally. Most strikingly, paralyzed mice treated with Lucid-MS reportedly regained the ability to walk—showing real hope that the drug could actually reverse some of MS’s worst effects instead of just slowing them down. This kind of breakthrough could change lives for people with MS, but QNTM’s progress has been held back by allegations of market manipulation.
Legitimate short selling—betting on a price decline through careful analysis and legal share borrowing—is completely different from illegal spoofing, which floods the market with fake orders to push prices down artificially. If these alleged manipulations hurt QNTM at the expense of MS patients who could benefit from a potential cure, this would rank among the most cynical forms of securities fraud ever seen: a calculated attack on a company, its funding, and ultimately the hope for a cure.
The US~Observer has exposed misconduct in government, law enforcement, and finance for over 30 years. We now focus on Andrea Nalyzyty, CIBC’s Chief Compliance Officer since at least 2015. Her alleged failures in oversight and response allegedly enabled serious market manipulation claims in Quantum BioPharma Ltd.’s (QNTM) $700 million+ lawsuit currently before Judge Edgardo Ramos in the Southern District of New York (Case No. 1:24-cv-07972).
Andrea Nalyzyty, as Chief Compliance Officer since at least 2015, allegedly allowed 747 spoofing episodes—deploying millions of baiting orders that allegedly depressed QNTM’s stock price by an average of 86.38 basis points per episode—to continue unchecked.
Andrea Nalyzyty’s tenure includes multiple compliance penalties:
- $1.225 million FCAC fine (2022) for undisclosed credit card over-limit fees impacting 677,000 customers.
- $3.4 million B.C. regulatory fine (2023) for improper mortgage discharge practices.
- $119,000 IIROC fine (2022) for supervisory failures, including misstated client risk profiles.
- $42 million combined CFTC/SEC penalty (2024) for off-channel communication violations that impaired trade supervision.
- $1.3 million Fintrac fine (2023) for anti-money laundering and terrorist-financing compliance breaches.
- $425,000 FINRA fine (2025) for inaccurate reporting of over 1.4 million OTC options positions across six years.
These repeated enforcement actions expose systemic compliance and supervision deficiencies under Andrea Nalyzyty’s leadership. For QNTM, such failures reportedly translated to distorted valuations, eroded investor trust, and constrained R&D funding essential for advancing Lucid-MS toward human trials.
If manipulation drove QNTM’s stock down, it was not a reasoned bet but calculated sabotage capable of bankrupting the company and derailing Lucid-MS. The human cost: prolonged suffering and lost hope for MS patients who could regain function if this product reaches market. Such conduct, if confirmed, stands as one of the most cynical securities frauds in history—trading lives for profit. Andrea Nalyzyty’s alleged failure to enforce controls and respond to warnings placed her at the center of this scheme.
CIBC’s track record reinforces the pattern: multiple enforcement actions during Andrea Nalyzyty’s tenure as Chief Compliance Officer, including the penalties listed above totaling tens of millions of dollars for lack of compliance, supervision, and reporting violations. The QNTM matter aligns with this history of control failures and regulatory breaches. Artificial price pressure starves life-saving research.
Regulators—the SEC, FINRA, IIROC, and Canadian authorities—must act decisively. Personal accountability is essential. Andrea Nalyzyty occupied the highest compliance position during the alleged violations. Supervisory lapses at this level are individual obligations under securities laws.
The US~Observer calls for targeted investigations of Andrea Nalyzyty: subpoenas for communications, scrutiny of compliance certifications, and assessment of whether her conduct or omissions justify civil penalties, disgorgement, or industry bars. Corporate fines alone are inadequate when leadership persists or advances. Investors and market integrity require more.
We will continue reporting until accountability is achieved. The stakes are immense: QNTM’s work could restore mobility through remyelination, but without consequences for Andrea Nalyzyty, innovation suffers. If CEO Harry Culham does not take decisive action against Andrea Nalyzyty—including internal investigation, removal from her role if allegations are verified, and full cooperation with regulators—he should be considered complicit in these alleged failures. Leadership silence in the face of repeated compliance breakdowns.
QNTM’s path—from preclinical mouse successes where mice regained the ability to walk, to human trials—embodies biotech potential. Yet it is threatened by unchecked manipulation. Andrea Nalyzyty’s compliance oversight allegedly enabled a record of penalties that erode confidence. Culham’s failure to act would only compound the problem. Regulators must hold them personally accountable to restore market fairness and ensure breakthroughs like Lucid-MS reach MS patients who need them most. Anything less perpetuates a system where cynical securities fraud prevails over medical progress.
For the full three-part W5/CTV investigative series detailing how mice began to walk again after treatment with Lucid-MS, visit the QNTM home website at quantumbiopharma.com.
US~Observer Accountability Summary: Nalyzyty (Primary) and Culham (Secondary)
- Andrea Nalyzyty — Chief Compliance Officer since at least 2015; allegedly ignored documented concerns from 2021 onward; present for multiple fines totaling millions for compliance and supervision failures (FCAC 2022, B.C. 2023, IIROC 2022, CFTC/SEC 2024, Fintrac 2023, FINRA 2025). Personal responsibility under FINRA Rule 3110 and equivalent Canadian rules.
- Harry Culham — As CEO, if he does not thoroughly investigate allegations against Andrea Nalyzyty and address the alleged failures if confirmed, he should be considered complicit.
The US~Observer demands regulators pursue Andrea Nalyzyty directly and hold Harry Culham accountable for inaction if allegations confirmed. The time for corporate fines alone is over.
Referenced External Stories and Reports
- Quantum BioPharma Ltd. (QNTM) Lawsuit Filing (S.D.N.Y. Case No. 1:24-cv-07972) – https://www.quantumbiopharma.com/quantum-biopharma-vs-banks
- CFTC & SEC 2024 Record-Keeping Fine Announcement – https://www.cftc.gov/PressRoom/PressReleases/8975-24
- Harrington Global Opportunity Fund v. CIBC World Markets (2022) – https://law.justia.com/cases/federal/district-courts/new-york/nysdce/1:2021cv00761/553152/147
- FCAC $1.225 Million Fine (2022) – https://www.canada.ca/en/financial-consumer-agency/services/industry/commissioner-decisions/decision-135.html
- B.C. Regulators $3.4 Million Fine (2023) – https://www.biv.com/news/economy-law-politics/bc-regulator-fines-cibc-34m-mortgage-documentation-failures-8273836
- Fintrac $1.3 Million Fine (2023) – https://fintrac-canafe.canada.ca/new-neuf/nr/2023-12-07-eng
- FINRA $425,000 Fine (2025) – https://fxnewsgroup.com/forex-news/regulatory/finra-fines-cibc-world-markets-corp-425k-for-alleged-rule-violations
- Save Canadian Mining Campaign – https://savecanadianmining.com/
- W5/CTV Three-Part Series on QNTM Spoofing (2025) – Available at quantumbiopharma.com (direct link to the series coverage)
Editor’s Note: These sources are publicly available and form the factual basis for the reported allegations and penalties. The US~Observer encourages readers to review the original documents for full context. Call the US~Observer at 602-960-4609 or submit a case submissions to enter your information confidentially and possibly qualify for the reward being offered by Quantum.
